HR 5247 · 115th Congress · Health

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018

Introduced 2018-03-13· Sponsored by Rep. Fitzpatrick, Brian K. [R-PA-8]· House

Bill Progress

1
Introduced
Committee
House Vote
4
Senate
5
Enacted
Latest: Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.(2018-04-09)

Recorded Votes

PassedHouse · 2018-03-21
Roll #121
Yea 267Nay 149
Democrats
35 Yea·147 Nay
Republicans
232 Yea·2 Nay
PassedHouse · 2018-03-21
Roll #121
Yea 267Nay 149
Democrats
35 Yea·147 Nay
Republicans
232 Yea·2 Nay
FailedHouse · 2018-03-21
Roll #120
Yea 182Nay 233
Democrats
181 Yea·1 Nay
Republicans
1 Yea·232 Nay
FailedHouse · 2018-03-13
Roll #102
Yea 259Nay 140
Democrats
32 Yea·138 Nay
Republicans
227 Yea·2 Nay

How Did Your Rep Vote?

Enter a ZIP code or representative's name

Plain Language Summary

[AI summary unavailable — showing source text] Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must publish annual summaries on any use of the drug in accordance with these provisions. The bill limits the liability of a sponsor, manufacturer, licensed physician, clinical investigator, or hospital that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.…

Summarized by Claude AI · Non-partisan · For informational purposes only

Cosponsors (20)

20 Republicans